company background image
FLGT logo

Fulgent Genetics NasdaqGM:FLGT Voorraadrapport

Laatste prijs

US$22.02

Marktkapitalisatie

US$687.1m

7D

2.7%

1Y

-15.6%

Bijgewerkt

07 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

Fulgent Genetics, Inc.

NasdaqGM:FLGT Voorraadrapport

Marktkapitalisatie: US$687.1m

FLGT Overzicht aandelen

Fulgent Genetics, Inc. levert samen met haar dochterondernemingen oplossingen voor klinische diagnostiek en therapeutische ontwikkeling aan artsen en patiënten in de Verenigde Staten en daarbuiten.

Fulgent Genetics, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Fulgent Genetics
Historische aandelenkoersen
Huidige aandelenkoersUS$22.02
52 Week HoogtepuntUS$30.68
52 Week LaagUS$18.76
Bèta1.5
11 maand verandering7.26%
3 maanden verandering-7.94%
1 Jaar Verandering-15.60%
33 jaar verandering-74.22%
5 jaar verandering98.20%
Verandering sinds IPO139.87%

Recent nieuws en updates

Fulgent Genetics: An NCAV Pick With Profit And Growth Potential

Sep 25

Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst

Sep 09

Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio

Jul 17
Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio

Recent updates

Fulgent Genetics: An NCAV Pick With Profit And Growth Potential

Sep 25

Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst

Sep 09

Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio

Jul 17
Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio

Fulgent Genetics: Growth Is Returning

Jun 06

Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

May 10
Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 07
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Mar 01
Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Feb 21

Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Jan 17
Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Dec 14
Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Aug 09
Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 09
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Apr 19
Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Jan 15
Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Dec 28
Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Nov 16
What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Oct 27
Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Wait For Fulgent Genetics To Grow Up

Oct 13

We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Sep 19
We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Sep 05
Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover

Jul 26

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Jul 21
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Jun 04
Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Fulgent Is Putting Its Cash Bonanza To Work

May 15

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

May 04
These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

Fulgent Genetics: Now The Going Could Get Much Tougher

Apr 10

Fulgent Genetics: COVID Bolstered The Underlying Business

Mar 17

Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business

Feb 27

Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy

Feb 09

Fulgent Genetics: Sell Volatility

Jan 26

Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet

Jan 25
Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet

Rendement voor aandeelhouders

FLGTUS HealthcareUS Markt
7D2.7%5.6%5.1%
1Y-15.6%7.3%37.7%

Rendement versus industrie: FLGT presteerde slechter dan de US Healthcare -sector, die het afgelopen jaar een rendement van 7.3 % opleverde.

Rendement versus markt: FLGT presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 37.7 % opleverde.

Prijsvolatiliteit

Is FLGT's price volatile compared to industry and market?
FLGT volatility
FLGT Average Weekly Movement4.6%
Healthcare Industry Average Movement6.8%
Market Average Movement6.2%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.9%

Stabiele aandelenkoers: FLGT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van FLGT is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
20111,184Ming Hsiehwww.fulgentgenetics.com

Fulgent Genetics, Inc. biedt samen met haar dochterondernemingen klinisch diagnostische en therapeutische ontwikkelingsoplossingen aan artsen en patiënten in de Verenigde Staten en internationaal. De klinische diagnostische oplossingen van het bedrijf omvatten moleculaire diagnostische tests; genetische tests; anatomische pathologische laboratoriumtests en testdiensten, zoals gastro-intestinale pathologie, dermatopathologie, urologische pathologie, borstpathologie, neuropathologie en hematopathologie; oncologische tests en testdiensten; en sequencerdiensten met betrekking tot erfelijke kanker, reproductieve gezondheid en andere ziekten. De therapeutische ontwikkelingsoplossingen richten zich op de ontwikkeling van kandidaat-geneesmiddelen voor de behandeling van een reeks kankers met behulp van een nanoencapsulatie en een platform voor gerichte therapie om het therapeutische venster en het farmacokinetische profiel van nieuwe en bestaande kankermedicijnen te verbeteren.

Fulgent Genetics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Fulgent Genetics zich tot de beurswaarde?
FLGT fundamentele statistieken
MarktkapitalisatieUS$687.13m
Inkomsten(TTM)-US$163.43m
Inkomsten(TTM)US$290.71m

2.3x

P/S-verhouding

-4.1x

Koers/Winstverhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
FLGT resultatenrekening (TTM)
InkomstenUS$290.71m
Kosten van inkomstenUS$177.04m
BrutowinstUS$113.67m
Overige uitgavenUS$277.10m
Inkomsten-US$163.43m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 08, 2024

Winst per aandeel (EPS)-5.39
Brutomarge39.10%
Nettowinstmarge-56.22%
Schuld/Eigen Vermogen Verhouding0.3%

Hoe presteerde FLGT op de lange termijn?

Bekijk historische prestaties en vergelijking